Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

NCT02482272 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: Lamivudine
DRUG: Adefovir
DRUG: Entecavir

Sponsor

Asan Medical Center